In a bold move, India's Drugs Controller General, Dr. Rajeev Singh Raghuvanshi, has announced a ban on two highly addictive opioids, tapentadol and carisoprodol, amid alarming reports of their role in exacerbating a health crisis across parts of West Africa. This development comes on the heels of a BBC investigation that unveiled the illegal exporting practices of the Mumbai-based pharmaceutical company, Aveo.
The BBC's inquiry revealed that Aveo had been distributing a dangerous combination of these opioids to nations including Ghana, Nigeria, and Cote D'Ivoire. As a result, Indian authorities conducted a raid on Aveo's facility, seizing their stock. The explicit communication from Dr. Raghuvanshi referred directly to the BBC’s findings that prompted the immediate action taken by the Indian government.
Tapentadol, an opioid known for its potency, combined with carisoprodol, which is banned in Europe due to its addictive nature, is believed to be fueling the surge in drug abuse in West African countries. Carisoprodol is permitted in the U.S. but only for limited durations, as it can lead to serious withdrawal symptoms involving anxiety and hallucinations.
Although globally unlicensed for use due to severe risks such as seizures and respiratory issues, this deadly cocktail has gained popularity as a cheap street drug within the region. Export data indicates that Aveo Pharmaceuticals, along with Westfin International, has exported millions of these tablets to West African markets. Local surveys indicate that Nigeria, with an alarming opioid abuse rate of approximately four million among its 225 million citizens, has become a principal consumer of these drugs.
The investigation highlighted a troubling reality: undercover videos captured at Aveo's factory showed company director Vinod Sharma discussing the appeal of their product to young Nigerians. In a shocking exchange, Sharma acknowledged the dangers while also implying that the profitability supersedes moral concerns.
Following the revelations, India's Food and Drug Administration has vowed to pursue further legal actions against Aveo and enhance inspections to prevent similar illicit activities in the future, reiterating a commitment to safeguarding public health and maintaining national integrity.
